Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Orelabrutinib in Healthy Males
NCT04441450Phase 1Completed
- Sponsor
- InnoCare Pharma
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orelabrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and small lymphocytic lymphoma (SLL), sponsored by InnoCare Pharma. Primary endpoints: Distribution ratio of total radioactivity in whole blood and plasma of [14C]ICP-022 up to 14 days and Quantitative analysis of total radioactivity in excreta after oral [14C] ICP-022 in healthy volunteers up to 14 days. Started Jul 2019; status: completed.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04441450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441450.